title: Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
abstract: In order to evaluate the proposed benefit of complete androgen blockade in the treatment of patients with advanced prostatic cancer, we initiated a multicenter prospective and randomized study. At the time of this report 99 patients with newly diagnosed, previously untreated prostatic cancer were randomly distributed to one of the following treatments: group I, orchiectomy plus antiandrogen Flutamide; group II, depot LH-RH analog Zoladex plus Flutamide; group III, orchiectomy alone, and group IV, Zoladex alone. Our preliminary data fail to demonstrate a superiority of total androgen blockade over partial androgen blockade in the treatment of patients with advanced cancer of the prostate.
authors.affiliation: Department of Urology, Ruhr University, Herne, FRG.
authors.forename: H
authors.initials: H
authors.lastname: Schulze
authors.forename: H
authors.initials: H
authors.lastname: Kaldenhoff
authors.forename: T
authors.initials: T
authors.lastname: Senge
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D002064:Buserelin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009919:Orchiectomy; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D011897:Random Allocation
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D017273:Goserelin; D005485:Flutamide; D002064:Buserelin